IP Library Granted Patent US 9,422,576
Granted Patent B2
US 9,422,576 · App. 14/409,134 · Granted Aug 23, 2016

Cell capable of producing adeno-associated virus vector

Inventors: Toshikazu Nishie (Shiga, JP); Fuyuko Takashima (Shiga, JP); Tatsuji Enoki (Shiga, JP); Junichi Mineno (Shiga, JP)
Assignee: TAKARA BIO INC.
C12N15/86C12N5/10C12N7/00C12N15/09C12N15/111C12N15/64C12P19/34C12N2310/141C12N2330/51C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,576
App. No.
14/409,134
Granted
Aug 23, 2016
Kind
B2
Abstract

According to the present invention, an AAV vector having a higher titer compared with those of conventional ones can be produced using a cell into which a nucleic acid capable of expressing miRNA is introduced artificially. An AAV vector produced using the cell and a composition containing the viral vector as an active ingredient are very useful as gene transfer means in the studies or clinical practice of gene therapies.

Claims (4)

1. An AAV vector-producing cell wherein the cell comprises and expresses at least one exogenous miRNA selected from the group consisting of hsa-miR-324, hsa-miR-196a1 and hsa-miR-342, and wherein the cell further comprises nucleic acid that expresses the elements essential for formation of the viral particle of an AAV vector, wherein the cell produces the AAV vector.

2. An AAV vector-producing cell, which is the cell according to claim 1 into which a nucleic acid to be enclosed in a virus has been introduced.

3. A process for producing an AAV vector, the process comprising a step of culturing the cell according to claim 2 .

4. A kit comprising a nucleic acid that expresses at least one miRNA selected from the group consisting of hsa-miR-324, hsa-miR-196a1 and hsa-miR-342 in combination with a nucleic acid that expresses the elements essential for formation of the viral particle of an AVV vector.

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 29, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039206/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2014
From: NISHIE, TOSHIKAZU; TAKASHIMA, FUYUKO; ENOKI, TATSUJI; MINENO, JUNICHI
To: TAKARA BIO INC.
Reel/Frame 034546/0866 →
Priority Claims (1)
JP 2012-152124 · Jul 6, 2012 · national
Continuity (1)
Related Publication 20150291980A1 · Oct 15, 2015